Etiopathogenesis of Differentiated Thyroid Carcinomas
DOI:
https://doi.org/10.3889/oamjms.2016.086Keywords:
Papillary thyroid carcinoma, Follicular thyroid carcinoma, radiation exposure, MAPK signalling network, PI3K-AKT pathwayAbstract
INTRODUCTION: Thyroid malignomas are a heterogeneous group of neoplasm consisting of most frequent differentiated encountered carcinomas, papillary and follicular thyroid carcinoma, then medullary thyroid carcinoma originating from neuroendocrine calcitonin-producing C-cells and rare forms of thyroid lymphomas arising from intrathyroidal lymphatic tissue, thyroid sarcomas and poorly differentiated anaplastic thyroid carcinoma. There are increasing numbers of epidemiological studies and publications that have suggested increased incidence rate of thyroid carcinomas. We have read, analysed and compare available reviews and original articles investigating different etiological factors in the development of thyroid carcinomas through Google Scholar and PubMed Database.
DISCUSSION: Aetiology involved in the development of thyroid carcinomas is multifactorial and includes external influences, as well as constitutional predispositions and genetic etiological factors. The actual effect of environmental and constitutional factors is on promoting genetic and epigenetic alterations which result in cell proliferation and oncogenesis. Until now are identified numerous genetic alterations, assumed to have an important role in oncogenesis, with MAPK and PI3K-AKT as crucial signalling networks regulating growth, proliferation, differentiation and cell survival/apoptosis.
CONCLUSION: This new molecular insight could have a crucial impact on diagnosis and also on improving and selecting an appropriate treatment to the patients with thyroid malignancies.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
De Groot LJ, Larsen PR, Hennemann G. The thyroid and its diseases, sixth edition. Churchill Livingstone, December 12, 1995.
Scopa CD. Histopathology of Thyroid Tumors. An Overview. Hormones. 2004;3(2):100-110. http://dx.doi.org/10.14310/horm.2002.11118 PMid:16982584
Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330-5. http://dx.doi.org/10.1002/cncr.20936 PMid:15739211
Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol. 2011;5(1):51-6. http://dx.doi.org/10.1007/s12105-010-0236-9 PMid:21221869 PMCid:PMC3037461
Li Volsi VA. Papillary thyroid carcinoma: an update. Modern Pathology. 2011;24:S1–S9. http://dx.doi.org/10.1038/modpathol.2010.129 PMid:21455196
Girardi FM, Barra MB, Zettler CG. Variants of papillary thyroid carcinoma: association with histopathological prognostic factors. Braz J Otorhinolaryngol. 2013;79(6):738-44. http://dx.doi.org/10.5935/1808-8694.20130135 PMid:24474487
Al-Brahim N, Asa SL. Papillary Thyroid Carcinoma An Overview. Arch Pathol Lab Med. 2006;130:1057–1062. PMid:16831036
Sobrinho-Simoes M, Eloy C, Magalhães J, Lobo C, Amaro T. Follicular thyroid carcinoma. Modern Pathology. 2011;24:S10–S18. http://dx.doi.org/10.1038/modpathol.2010.133 PMid:21455197
McHenry CR, Phitayakorn R. Follicular Adenoma and Carcinoma of thyroid gland. The Oncologist. 2011;16:585-593. http://dx.doi.org/10.1634/theoncologist.2010-0405 PMid:21482585 PMCid:PMC3228182
D'Avanzo A, Treseler P, Ituarte PHG, Wong M, Streja L, Greenspan FS, et al. Follicular Thyroid Carcinoma: Histology and Prognosis. Cancer. 2004;100:1123–9. http://dx.doi.org/10.1002/cncr.20081 PMid:15022277
Ruggeri RM, Campenni A, Baldari S, Trimarchi F, Trovato M. What is new on thyroid cancer biomarkes. Biomark Insights. 2008;3:237-252. PMid:19578508 PMCid:PMC2688342
Burns WR, Zeiger MA. Differentiated thyroid cancer. Semin Oncol. 2010;37(6):557-66. http://dx.doi.org/10.1053/j.seminoncol.2010.10.008 PMid:21167375
Davies L, Welch HG. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164-2167. http://dx.doi.org/10.1001/jama.295.18.2164 PMid:16684987
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid [Internet]. Mary Ann Liebert Inc; 2016;26(1):1–133.
La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: A global overview. Int J Cancer. 2015;136:2187–2195. http://dx.doi.org/10.1002/ijc.29251 PMid:25284703
Moriss LG, Sikora AG, Tosteson TD, Davis L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013;23(7):885-91. http://dx.doi.org/10.1089/thy.2013.0045 PMid:23517343 PMCid:PMC3704124
Hodgson NC, Button J, Solorzano CC. Thyroid Cancer: Is the Incidence Still Increasing? Ann Surq Oncol. 2004;11(12):1093-97. http://dx.doi.org/10.1245/ASO.2004.03.066 PMid:15576834
Favus MJ, Schneider AB, Stachura ME, Arnold JE, Rio UY, Pinski SM, et al. Thyroid Cancer Occurring as a Late Consequence of Head-and-Neck Irradiation — Evaluation of 1056 Patients. N Engl J Med. 1976; 294:1019-1025. http://dx.doi.org/10.1056/NEJM197605062941901 PMid:1256510
Refetoff S, Harrison J, Karanfilski B, Kaplan EL, De Groot LJ, Bekerman C. Continuing Occurrence of Thyroid Carcinoma after Irradiation to the Neck in Infancy and Childhood. N Engl J Med. 1975; 292:171-175. http://dx.doi.org/10.1056/NEJM197501232920402 PMid:122783
Tucker MA, Morris Jones PH, Boice JD, Robison LL, Stone BJ, Stovall M, Jenkin RDT. Therapeutic Radiation at a Young Age Is Linked to Secondary Thyroid Cancer. Cancer Research. 1991; 51:2885-88. PMid:1851664
Furukawa K, Preston D, Funamoto S, Yonehara S, Ito M, Tokuoka S, et al. Long-term trend of thyroid cancer risk among Japanese atomic bomb survivors: 60 years after exposure. Int J Cancer. 2013; 132(5):1222–26. http://dx.doi.org/10.1002/ijc.27749 PMid:22847218 PMCid:PMC3910094
Schonfeld SJ, Lee C, de González AB. Medical exposure to radiation and thyroid cancer. Clin Oncol (R Coll Radiol). 2011;23(4):244-50. http://dx.doi.org/10.1016/j.clon.2011.01.159 PMid:21296564
Cardis E, Hatch M. The Chernobyl accident — an epidemiological perspective, Clin Oncol (R Coll Radiol). 2011;23(4): 251–260. http://dx.doi.org/10.1016/j.clon.2011.01.510 PMid:21396807 PMCid:PMC3107017
Knobel M, Medeiros-Neto G. Relevance of Iodine Intake as a Reputed Predisposing Factor for Thyroid Cancer. Arq Bras Endocrinol Metabol. 2007;51(5):701-12. http://dx.doi.org/10.1590/S0004-27302007000500007 PMid:17891233
Horn-Ross PL, Moriss JS, Lee M, West DW, Whittemore AS, McDougall IR, et al. Iodine and Thyroid Cancer Risk among Women in a Multiethnic Population: The Bay Area Thyroid Cancer Study. Cancer Epidemiol Biomarkers Prev. 2001;10(9):979–985. PMid:11535551
Schumberger M, Pacini F, Tutle RM. Thyroid tumors, Forth edition, Paris: Institute Medico-Educatif, 2015.
Chen GG, Vlantis AC, Zeng Q, Van Hasselt CA. Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets. 2008;8:367-77. http://dx.doi.org/10.2174/156800908785133150 PMid:18690843
Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age and multinodularity. AmJ Med. 1992;93:363-69. http://dx.doi.org/10.1016/0002-9343(92)90164-7
Schlumberg MJ. Papillary thyroid carcinoma. Orphanet encyclopedia, March 2004.
Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3): 184-199. http://dx.doi.org/10.1038/nrc3431 PMid:23429735 PMCid:PMC3791171
Wiench M, Wloch J, Oczko M, Gubala E, Jarzab B. Rearrangement of the RET gene in papillary thyroid carcinoma. Wiad Lek. 2001;54(Suppl 1):64-71. PMid:12182064
Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002;13(1):3-16. http://dx.doi.org/10.1385/EP:13:1:03
Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245-62. http://dx.doi.org/10.1677/erc.1.0978 PMid:15947100
Nozhat Z, Hedayati M. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas. Mol Diagn Ther. 2016;20(1):13-26. http://dx.doi.org/10.1007/s40291-015-0175-y PMid:26597586
Chien W, Koeffler HP. Molecular Biology of Thyroid Cancer. G.D. Braunstein (ed.). Thyroid Cancer, Endocrine Updates 30, 35. Springer Science+Business Media, LLC 2012.
Brehar AC, Brehar FM, Dumitrache C, Parhon CI, Arseni B, Davila C. Genetic and epigenetic alterations in differentiated thyroid carcinoma. J Med Life. 2013;6(4):403-8. PMid:24868250 PMCid:PMC4034295
Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, Kolch W. Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem J. 2005;392(Pt 2):249-61. http://dx.doi.org/10.1042/BJ20050908 PMid:16293107 PMCid:PMC1316260
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0